ARTICLE | Clinical News
VX15/2503: Phase II started
July 20, 2015 7:00 AM UTC
Vaccinex began the double-blind, placebo-controlled Phase III SIGNAL trial to evaluate 20 mg/kg IV VX15/2503 once monthly in up to 84 patients with late prodromal and early manifest HD. ...